Cargando…

WHO Is Recommending against the Use of COVID-19 Convalescent Plasma in Immunocompromised Patients?

Detalles Bibliográficos
Autores principales:	Franchini, Massimo, Casadevall, Arturo, Joyner, Michael J., Focosi, Daniele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9867306/ https://www.ncbi.nlm.nih.gov/pubmed/36676084 http://dx.doi.org/10.3390/life13010134

Ejemplares similares

Convalescent plasma for COVID-19. TSUNAMI is not the final word
por: Franchini, Massimo, et al.
Publicado: (2022)

COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis
por: Senefeld, Jonathon W., et al.
Publicado: (2023)

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent plasma for COVID-19 in oncohematological patients: a call for revision of the European Conference on Infections in Leukemia-9 (ECIL-9) guidelines
por: Focosi, Daniele, et al.
Publicado: (2023)

On the Need to Determine the Contribution of Anti-Nucleocapsid Antibodies as Potential Contributors to COVID-19 Convalescent Plasma Efficacy
por: Focosi, Daniele, et al.
Publicado: (2022)

Convalescent plasma in outpatients with COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

Analysis of anti-Omicron neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J, et al.
Publicado: (2022)

Analysis of anti-SARS-CoV-2 Omicron-neutralizing antibody titers in different vaccinated and unvaccinated convalescent plasma sources
por: Sullivan, David J., et al.
Publicado: (2022)

High-Dose Convalescent Plasma for Treatment of Severe COVID-19
por: Focosi, Daniele, et al.
Publicado: (2022)

COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
por: Focosi, Daniele, et al.
Publicado: (2021)

Convalescent plasma to deliver therapeutic antibodies against COVID-19
por: Senefeld, Jonathon W., et al.
Publicado: (2022)

Home and Out-of-Hospital Therapy with COVID-19 Convalescent Plasma in Europe
por: Focosi, Daniele, et al.
Publicado: (2022)

Impact of pathogen-reduction technologies on COVID-19 convalescent plasma potency
por: Focosi, D., et al.
Publicado: (2021)

Use of convalescent plasma in the treatment of COVID-19
por: Joyner, Michael J., et al.
Publicado: (2023)

Guidance on the Use of Convalescent Plasma to Treat Immunocompromised Patients With Coronavirus Disease 2019
por: Bloch, Evan M, et al.
Publicado: (2023)

The emergency use authorization for COVID‐19 convalescent plasma reduced mortality
por: Paneth, Nigel, et al.
Publicado: (2023)

The Assessment of Convalescent Plasma Efficacy against COVID-19
por: Casadevall, Arturo, et al.
Publicado: (2020)

Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews
por: Franchini, Massimo, et al.
Publicado: (2021)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J, et al.
Publicado: (2022)

Plasma after both SARS-CoV-2 boosted vaccination and COVID-19 potently neutralizes BQ.1.1 and XBB.1
por: Sullivan, David J., et al.
Publicado: (2023)

Polyclonal immunoglobulins for COVID-19 pre-exposure prophylaxis in immunocompromised patients
por: Focosi, Daniele, et al.
Publicado: (2023)

Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy
por: Casadevall, Arturo, et al.
Publicado: (2020)

Analysis of Immune Escape Variants from Antibody-Based Therapeutics against COVID-19: A Systematic Review
por: Focosi, Daniele, et al.
Publicado: (2021)

SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients constitute a public health concern
por: Casadevall, Arturo, et al.
Publicado: (2023)

The art of the possible in approaching efficacy trials for COVID19 convalescent plasma
por: Focosi, Daniele, et al.
Publicado: (2021)

Convalescent Plasma Therapy for COVID-19: State of the Art
por: Focosi, Daniele, et al.
Publicado: (2020)

Convalescent plasma use in the USA was inversely correlated with COVID-19 mortality
por: Casadevall, Arturo, et al.
Publicado: (2021)

Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients—An Open-Label Phase II Clinical Trial
por: Grubovic Rastvorceva, Rada M., et al.
Publicado: (2022)

Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor–recipient differences in concentration of neutralizing antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

Rethinking the role of COVID-19 convalescent plasma in the critically ill
por: Casadevall, Arturo, et al.
Publicado: (2023)

COVID-19 Convalescent Plasma and Concomitant Therapies in PassITON
por: Casadevall, Arturo, et al.
Publicado: (2022)

COVID19 immune plasma donation after vaccination: pros and cons.
por: Focosi, Daniele, et al.
Publicado: (2021)

How Safe Is COVID-19 Convalescent Plasma?
por: Franchini, Massimo, et al.
Publicado: (2021)

COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma
por: Sullivan, David, et al.
Publicado: (2023)

Convalescent Plasma for the Treatment of Severe COVID-19
por: Franchini, Massimo, et al.
Publicado: (2021)

Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Plasma Hesitancy cost lives?
por: Casadevall, Arturo, et al.
Publicado: (2021)

Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19
por: Rodionov, Roman N, et al.
Publicado: (2021)

Convalescent Plasma for Infectious Diseases: Historical Framework and Use in COVID-19
por: Ripoll, Juan G., et al.
Publicado: (2021)

Why should we use convalescent plasma for COVID-19?
por: Franchini, Massimo
Publicado: (2020)

SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies
por: Focosi, Daniele, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5orpgofg3nfskni54clj1iol9g